Palmitoylethanolamide powder (544-31-0) Mechanism of Action

Palmitoylethanolamide activates the energy-boosting, fat-burning, and anti-inflammatory PPAR alpha. By activating this important protein, PEA prevents the activity of pro-inflammatory genes and the production of many inflammatory substances. Palmitoylethanolamide reduces the activity of this pituitary gland FAAH that breaks down natural cannabinoid anandamide. This increases the amount of calming anandamide inside your entire body, helping to combat pain and increase relaxation. It may also activate cannabinoid receptors (CB2 and CB1).

Palmitoylethanolamide contains the palmitic acid in its own structure. The starting point for making PEA in the body will be just this saturated fatty acid. But only increasing your intake of palmitic acid or other dietary fats won't affect palmitoylethanolamide (pea) bulk powder production in the body. That is because the body will use PEA just as it has to compensate for inflammation or pain, and also its levels will also normally vary through your day. The very optimal/optimally way to find some great benefits of PEA are standardized nutritional supplements, or alternatively PEA-rich food items.

PEA Advantages and Uses

Chronic Regional Pain Syndrome (CRPS)

Chronic regional pain syndrome (CRPS) describes a illness characterized by chronic, debilitating, and often-untreatable pain, changes to the quality of the afflicted individual's hair, skin, and nails, tremors/muscle spasms, and insomnia. In rare and acute cases, individuals afflicted by CRPS may expertise nausea, muscle atrophy, and/or muscle contractures.

Nerve pain

Nerve pain encompasses a broad range of chronic signs that are triggered by damage to the nerves that transfer information in the spinal cord to skin and muscles. pea is well-understood to be an efficient pain modulator, and thus has emerged within fairly latest research as a possible therapeutic agent for several sorts of chronic neuropathic pain. PEA is thought to be one among the best supplements to naturally deal with nerve painkillers.

Glaucoma

Some new research has pointed into palmitoylethanolamide (pea) bulk powder as a potential natural retinoprotectant, or an agent that can combat pathogenic threats to the retinas and thus the vision. A 2015 assessment released from the Journal of Opthalmology evaluated palmitoylethanolamide's therapeutic results in the treatment of glaucomathat the second most prevalent cause of blindness. One randomized clinical trial in the review examined the consequences of orally administered PEA in forty-two patients having an elevated intraocular pressure (or IOP, a significant contributing factor in glaucoma advancement ) and unearthed that oral PEA significantly paid off the markers of IOP after two weeks of treatment.

Arthritis

A 2017 study published by BMC Veterinary Research evaluated the therapeutic results of palmitoylethanolamide and quercetin, a plant flavonoid, in the treatment of osteoarthritis in animal issues. Researchers administered an oral mix of palmitoylethanolamide co-ultramicronized using quercetin (PEA-Q) to laboratory rats demonstrating inflammatory and osteoarthritic pain and found that PEA-Q decreased both inflammatory and hyperalgesic responses. Further, both PEA-Q enhanced locomotor work, secure cartilage against histological damage, and paid off mechanical allodynia.

Influenza and/or Shared Cold

However additional research is required to make a well rounded pharmacological account of efficacy, some clinical signs has indicated that palmitoylethanolamide may have an anti-influenza mechanism of action. A research review released by the International Journal of Inflammation evaluated data synthesized from PubMed on the past fifty years and found 6 clinical trials concentrating on palmitoylethanolamide's therapeutic efficacy in the treatment of respiratory inflammation and flu. Available evidence points into palmitoylethanolamide as an entity capable of attenuating intestinal trauma and inflammation and soothes proinflammatory cytokine production in parasites that are parasitic. Researchers guessed that PEA may be able to de-escalate influenza and cool symptoms by down-modulating inflammatory cytokines and so restraining disease progression.

PEA Dosage

In a 2017 safety evaluation, palmitoylethanolamide was determined to not cause genotoxic effects in human cells at doses of 1,000 mg/kg for a preliminary 14-day examine. The ld-50, or lethal dose, was greater than 2,000 mg/kg. Palmitoylethanolamide is typically available in capsule form, frequently at a standard dosage of 400 mg per pill, taken twice or twice daily.

Palmitoylethanolamide can be eaten in powder and/or capsule form. It is also available as a non-steroidal topical cream for the aims of alleviating pain and inflammation.